STEM Minnesota
SEE OTHER BRANDS

Get your science and technology news from Minnesota

STEM Minnesota: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on STEM Minnesota.

Press releases published on June 23, 2025

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide alone Icovamenib …

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

- Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage …

Built for the Future: TwentyOneVC Supports Investment Planning

Built for the Future: TwentyOneVC Supports Investment Planning

LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- TwentyOneVC, a financial company, has unveiled a new suite of planning tools aimed at helping users build and manage long-term financial strategies with a generational mindset. The update signals a shift in the …

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)

New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX (CAIX)-expressing tumors Part D builds on promising imaging data demonstrated in Part A of the study for …

Official Launch of Virtune Coinbase 50 Index ETP Marked by Bell Ringing in Frankfurt

Official Launch of Virtune Coinbase 50 Index ETP Marked by Bell Ringing in Frankfurt

Stockholm, June 23, 2025 – Virtune, the Swedish regulated crypto asset manager, celebrated the official launch of its latest exchange-traded product, the Virtune Coinbase 50 Index ETP, with a ceremonial bell ringing at Deutsche Börse Xetra in Frankfurt on …

Officiell lansering av Virtune Coinbase 50 Index ETP markerad med bell ringning i Frankfurt

Officiell lansering av Virtune Coinbase 50 Index ETP markerad med bell ringning i Frankfurt

Stockholm, 23 juni 2025 – Virtune, den svenska reglerade kapitalförvaltaren för kryptotillgångar, firade den 17 juni den officiella lanseringen av sin senaste börshandlade produkt, Virtune Coinbase 50 Index ETP, med en högtidlig bell ringing-ceremoni på …

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global …

LightSolver Selected as 2025 Technology Pioneer by the World Economic Forum

LightSolver Selected as 2025 Technology Pioneer by the World Economic Forum

TEL AVIV, Israel , June 23, 2025 (GLOBE NEWSWIRE) -- LightSolver, inventors of a new laser-based HPC computing paradigm, today announced that it has been named a 2025 Technology Pioneer by the World Economic Forum (WEF). With this recognition, LightSolver …

$PUMPIT Relaunches as $BOG on Pump.fun - Revives Legendary Bogdanoff Crypto Meme Legacy

$PUMPIT Relaunches as $BOG on Pump.fun - Revives Legendary Bogdanoff Crypto Meme Legacy

PARIS, FRANCE, June 23, 2025 (GLOBE NEWSWIRE) -- The spirit of crypto meme culture made a triumphant return with the recent relaunch of $PUMPIT as $BOG, the only memecoin officially backed by the Bogdanoff family and inspired by the iconic legacy of Igor …

BCC Mining cloud mining supports BTC/XRP one-click mining

BCC Mining cloud mining supports BTC/XRP one-click mining

New York City, NY, June 23, 2025 (GLOBE NEWSWIRE) -- Tensions in the Middle East have increased volatility in the cryptocurrency market, and investors are looking for safer ways to hedge their investments. BCC Mining has become a popular investment option …

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki1,2 Fremanezumab demonstrated sustained effectiveness and a favourable safety and tolerability …

EveLab Insight Debuts Dynamic Wrinkle Detection Technology at VivaTech 2025, Shaping the Future of AI-Powered Skin Wellness

EveLab Insight Debuts Dynamic Wrinkle Detection Technology at VivaTech 2025, Shaping the Future of AI-Powered Skin Wellness

SINGAPORE, June 23, 2025 (GLOBE NEWSWIRE) -- EveLab Insight, a global leader in AI skin analysis technology, successfully concluded its debut at VivaTech 2025, Europe's premier innovation and technology event. From June 11-14, the company showcased a major …

Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML

Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML

60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) EO2463 plus R2 was well tolerated in patients with follicular and marginal zone lymphoma EO2463 plus R2 combination treatment resulted in …

141,959 Orion Corporation A shares converted into B shares

141,959 Orion Corporation A shares converted into B shares

ORION CORPORATION  STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 23 June 2025 at 9.30 EEST          141,959 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of …

141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi

141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi

ORION OYJ         PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT          23.6.2025 KLO 9.30          141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla on muunnettu 141 959 A- …

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease

PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB’S POTENTIAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION THIS PUBLICATION CORROBORATES NEW ANALYSIS FROM THE …

AB Science - De nouvelles données évaluées par des pairs apportent des preuves solides du potentiel du masitinib dans le traitement de la maladie d’Alzheimer

AB Science - De nouvelles données évaluées par des pairs apportent des preuves solides du potentiel du masitinib dans le traitement de la maladie d’Alzheimer

COMMUNIQUE DE PRESSE DE NOUVELLES DONNÉES ÉVALUÉES PAR DES PAIRS APPORTENT DES PREUVES SOLIDES DU POTENTIEL DU MASITINIB DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER GRÂCE À UN DOUBLE MÉCANISME D'AMÉLIORATION COGNITIVE ET DE NEUROPROTECTION CETTE …

Galapagos Appoints Aaron Cox as Chief Financial Officer

Galapagos Appoints Aaron Cox as Chief Financial Officer

Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership  Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext …

Galapagos benoemt Aaron Cox als Chief Financial Officer

Galapagos benoemt Aaron Cox als Chief Financial Officer

Voormalig CFO van Horizon vervoegt Galapagos met diepgaande expertise in internationale bedrijfsfinanciering, fusies en overnames, bedrijfsontwikkeling en strategisch leiderschap Mechelen, België; 23 juni 2025, 07:30 CET; gereglementeerde informatie - …

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service